Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00121641 · ClinicalTrials.gov registry record · Phase 3
Saxagliptin Treatment in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,035
- Enrollment target
NCT00121641: Completed Phase 3 study, sponsored by AstraZeneca.
NCT00121641 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 1,035 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (34% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00121641, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,035 participants
- Enrollment target
Study Summary
The purpose of this clinical research study is to learn whether saxagliptin (BMS-477118) is more effective than placebo as a treatment for type 2 diabetic subjects who are not sufficiently controlled with diet and exercise
Primary Outcome
To compare the change from baseline in HbA1c achieved with each dose of saxagliptin versus placebo in treatment naive subjects with type 2 diabetes who have inadequate glycemic control defined as A1C ≥7.0% and ≤10.0%.
Interventions
- DRUG Metformin
- DRUG Saxagliptin
- DRUG Placebo matching Saxagliptin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,035 participants |
| Start Date | 2005-07 |
| Est. Completion | 2010-02 |
| Phase | Phase 3 |
What the finished NCT00121641 record still lists
NCT00121641 is an interventional study that assigns participants to a tested intervention. Its 1,035 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (34% higher).
The record links to 0 conditions, and to 3 interventions - of which Metformin is the first listed.
NCT00121641 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00121641 about?
NCT00121641 is a clinical study titled "Saxagliptin Treatment in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise". The purpose of this clinical research study is to learn whether saxagliptin (BMS-477118) is more effective than placebo as a treatment for type 2 diabetic subjects who are not sufficiently controlled with diet and exercise
What is the current status of trial NCT00121641?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,035 participants. The study started on 2005-07. Estimated completion is 2010-02.
What interventions are being tested in trial NCT00121641?
The interventions under investigation include: Metformin (DRUG), Saxagliptin (DRUG), Placebo matching Saxagliptin (DRUG).
Who is sponsoring clinical trial NCT00121641?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00121641's enrollment target sits among peer trials
1,035 287th of 2000 higher than 1,713 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05037682 · 1,035 participants · NA
Pain and Opioid Management in Older Adults
- NCT07282600 · 1,035 participants · Phase 3
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
- NCT07345767 · 1,038 participants · NA
Hypknowledge Nationwide Sleep Extension
- NCT07084363 · 1,032 participants · NA
Quantitative Versus qUAlitative NeuromoniToring of neUroMuscular Block for Non-cardiothoracic Surgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia